Investors seeking to outperform the market often focus on hand-picking stocks. Selecting the right ones has proven to be a key factor in boosting wealth.
After finishing at $9.12 in the prior trading day, Arcus Biosciences Inc (NYSE: RCUS) closed at $8.40, down -7.89%. In other words, the price has decreased by -$7.89 from its previous closing price. On the day, 0.72 million shares were traded. RCUS stock price reached its highest trading level at $9.085 during the session, while it also had its lowest trading level at $8.31.
Ratios:
Our goal is to gain a better understanding of RCUS by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 4.50 and its Current Ratio is at 4.50. In the meantime, Its Debt-to-Equity ratio is 0.33 whereas as Long-Term Debt/Eq ratio is at 0.30.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, H.C. Wainwright on February 26, 2025, Upgraded its rating to Buy and sets its target price to $24 from $18 previously.
On October 21, 2024, H.C. Wainwright started tracking the stock assigning a Neutral rating and target price of $20.
On October 08, 2024, Wells Fargo started tracking the stock assigning a Overweight rating and target price of $29.Wells Fargo initiated its Overweight rating on October 08, 2024, with a $29 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Feb 27 ’25 when KANEKO YASUNORI bought 20,000 shares for $10.06 per share. The transaction valued at 201,200 led to the insider holds 28,400 shares of the business.
ROSEN TERRY J bought 19,800 shares of RCUS for $201,465 on Feb 27 ’25. The Chief Executive Officer now owns 2,554,160 shares after completing the transaction at $10.18 per share. On Feb 18 ’25, another insider, GILEAD SCIENCES, INC., who serves as the 10% Owner of the company, bought 1,363,636 shares for $11.00 each. As a result, the insider paid 14,999,996 and bolstered with 31,424,760 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, RCUS now has a Market Capitalization of 965277568 and an Enterprise Value of 70067944. For the stock, the TTM Price-to-Sale (P/S) ratio is 3.45 while its Price-to-Book (P/B) ratio in mrq is 1.60. Its current Enterprise Value per Revenue stands at 0.272 whereas that against EBITDA is -0.234.
Stock Price History:
The Beta on a monthly basis for RCUS is 1.48, which has changed by -0.538715 over the last 52 weeks, in comparison to a change of 0.10063088 over the same period for the S&P500. Over the past 52 weeks, RCUS has reached a high of $19.11, while it has fallen to a 52-week low of $8.82. The 50-Day Moving Average of the stock is -26.76%, while the 200-Day Moving Average is calculated to be -43.48%.
Shares Statistics:
The stock has traded on average 932.67K shares per day over the past 3-months and 859430 shares per day over the last 10 days, according to various share statistics. A total of 92.20M shares are outstanding, with a floating share count of 64.90M. Insiders hold about 38.68% of the company’s shares, while institutions hold 49.40% stake in the company. Shares short for RCUS as of 1740700800 were 6876782 with a Short Ratio of 7.37, compared to 1738281600 on 6379345. Therefore, it implies a Short% of Shares Outstanding of 6876782 and a Short% of Float of 11.709999999999999.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
The stock of Arcus Biosciences Inc (RCUS) is currently drawing attention from 4.0 analysts actively involved in the ongoing evaluation and rating process.The consensus estimate for the next quarter is -$1.0, with high estimates of -$0.89 and low estimates of -$1.21.
Analysts are recommending an EPS of between -$3.56 and -$4.85 for the fiscal current year, implying an average EPS of -$4.01. EPS for the following year is -$4.25, with 5.0 analysts recommending between -$3.23 and -$5.17.
Revenue Estimates
8 analysts predict $38.61M in revenue for the current quarter. It ranges from a high estimate of $60M to a low estimate of $20M. As of the current estimate, Arcus Biosciences Inc’s year-ago sales were $145MFor the next quarter, 8 analysts are estimating revenue of $37.36M. There is a high estimate of $65M for the next quarter, whereas the lowest estimate is $20M.
A total of 10 analysts have provided revenue estimates for RCUS’s current fiscal year. The highest revenue estimate was $263M, while the lowest revenue estimate was $80M, resulting in an average revenue estimate of $154.46M. In the same quarter a year ago, actual revenue was $258MBased on 10 analysts’ estimates, the company’s revenue will be $181.89M in the next fiscal year. The high estimate is $283.67M and the low estimate is $40M.
